Log In
BCIQ
Print this Print this
 

Cx601

  Manage Alerts
Collapse Summary General Information
Company TiGenix N.V.
DescriptionAllogeneic expanded adipose derived stem cells
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Stem cell
Latest Stage of DevelopmentRegistration
Standard IndicationCrohn's disease
Indication DetailsTreat anal fistula; Treat complex perianal fistulas in Crohn's disease (CD) patients
Regulatory Designation U.S. - Special Protocol Assessment (Treat complex perianal fistulas in Crohn's disease (CD) patients)
PartnerTakeda Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$519.2M

$27.8M

$355.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/05/2016

$433.0M

$27.8M

$355.0M

05/09/2011

$86.2M

0

0

Get a free BioCentury trial today